PRCA Treatment: Isatuximab Study

We are studying whether the drug isatuximab can help patients with pure red cell aplasia after stem cell transplantation. This trial compares its effects to standard supportive care to see which is more effective.

>2 years6-10 visitsEfficacy phase (II)No PlaceboStandard MedicinesInjectionHematologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Sarclisa
Sarclisa is a medicine used to treat multiple myeloma, a type of blood cancer.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Isatuximab
Isatuximab is a substance that helps the immune system target and destroy cancerous plasma cells in multiple myeloma.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centre Hospitalier Universitaire Grenoble Alpes
Hématologie
Allières-et-Risset, France
Centre Hospitalier Universitaire De Caen Normandie
Hématologie
Caen, France
Hopital D'Instruction Des Armees Percy
Hématologie
Clamart, France
Sponsor: Assistance Publique Hopitaux De Paris
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.